Videos

In part 2 of this panel discussion, experts discuss how they define traditional versus nontraditional oncology pharmacy roles and where roles within industry fit in.

Following the release of new guidelines on childhood obesity, some experts raised concerns about the safety of using anti-obesity drugs in young people.

Pharmacy departments can be one of the most expensive departments in a cancer center practice, but the revenue generated for its services typically far outpaces associated costs.

AI-enabled algorithms can also augment clinical decision making for health care professionals using real-time data analysis and decision support to treat patients more efficiently and accurately.

John E. Clark, PharmD, MS, FASHP, FFSHP, Director, Diversity, Equity, and Inclusion at the Taneja College of Pharmacy, University of South Florida, discusses the importance of addressing social determinants of health to improve patient outcomes.

Through automated tools related to scheduling, prior authorization, and radiation planning tasks, there are efforts to shorten the time from diagnosis to treatment to improve patient outcomes.

Deep learning AI models like ChatGPT health care edition, coupled with applications targeting pain points in practice workflow, present a very exciting vision for the future.

Sheldon Litwin, MD, a cardiologist at the Medical University of South Carolina, discussed the significant recent advances in anti-obesity drugs.

Pharmacy technicians and pharmacy technician leadership from UPMC Presbyterian discuss the importance of diverse representation.

Pharmacy technicians and pharmacy technician leadership from UPMC Presbyterian discuss what being a Black health care workers means to them.

Donna Ryan, MD, discussed her presentation about pharmacological approaches for obesity, which patients they are indicated for, and considerations for pharmacists.

Neal Dave, PharmD, reviews the therapeutic options considered for patients with a T315I mutation identified during mutational analysis.

Brandon Dyson, PharmD, BCOP, BCPS, reviews the challenges in treatment of resistant chronic myeloid leukemia and Philadelphia chromosome-positive ALL.

Although scientists have long been working on anti-obesity medications, several key failures in recent decades have made this a challenge.

In an interview with Pharmacy Times, Anastasia Armbruster, PharmD, FACC, BCCP, discussed her presentation at the American College of Cardiology 2023 Scientific Session.

Although pharmacokinetics and dynamics can be complex, particularly in patients with cancer, pharmacists play a key role in the various considerations and treatment decisions.

Health care providers can manage “fake news” about statins, including their indications and misinformation regarding liver and kidney damage.

In addition to the hundreds of sessions and events, ACC has partnered with the World Heart Federation, bringing an international focus to the meeting.

In part 1 of this panel discussion, experts address how they define traditional versus nontraditional oncology pharmacy roles today, as well as the benefits and drawbacks of pursuing such a career path based on their experience.

American College of Cardiology President Edward Fry, MD, FACC, discussed what attendees can look forward to at the 2023 Scientific Sessions.

Dr Haumschild discusses the substantial impact of clinical pathways in the treatment of ovarian cancer.

The significance of multidisciplinary teams in ovarian cancer treatment is highlighted.

David Dalton, PharmD, CEO of Univec, addresses how the pharmacist is ideally positioned to support the technological transformation that is occurring in health care today.

In their closing thoughts, Mr Haumschild leads the panel in a discussion regarding treatments on the horizon for patients with relapsed/refractory multiple myeloma.

Toxicity management associated with anti-CD38 drugs is highlighted by a panel of medical experts.

Brandon Dyson, PharmD, BCOP, BCPS, provides an overview of how tyrosine kinase inhibitor resistance is identified in patients with chronic myeloid leukemia and Philadelphia chromosome-positive ALL.

Experts review how the rates of tyrosine kinase inhibitor resistance affect treatment options for these populations and how to sequence treatment for these patients.

Two members of a clinical-stage authoring group discuss education programs and the alternative career path of medical writing, which can offer hybrid/virtual work-life balance opportunities.

Dr Haumschild explores considerations for safe and appropriate dosing for patients receiving PARP inhibitor therapy.

Ryan Haumschild, PharmD, MS, MBA, opens a discussion surrounding the use of PARP inhibitors within the treatment landscape for ovarian cancer.